Literature DB >> 1561806

Hereditary melanoma and the search for the melanoma gene.

R F Kefford1.   

Abstract

The discovery and characterization of growth regulatory genes, in the form of oncogenes, and their counterparts, tumor suppressor (TS) or antioncogenes, has vastly expanded the basic understanding of tumorigenesis. Human solid tumors, such as colorectal cancer, for which the molecular genetics have been most clearly defined, display progressive evolution from cellular dysplasia to anaplasia and metastasis through the stepwise accumulation of genetic defects, involving the regulation and expression of both oncogenes and TS genes. The study of basic genetic abnormalities in melanoma and the identification of the most fundamental of these is critical both to the understanding of abnormal melanocyte proliferation and its potential pharmacologic or immunologic regulation, and also to the identification and screening of patients at high risk for the development of melanoma. The search for such genetic abnormalities has included an analysis of melanomas for defects in known characterized oncogenes and TS genes, and, more importantly, the use of families with hereditary melanoma (HM) and dysplastic nevi in an endeavor to find the melanoma gene. The importance of HM is fundamental, since in the case of other hereditary cancer syndromes for which the genetic basis has been identified, the same or similar genetic abnormalities underlie sporadic tumors of the same tissue type. Thus HM is likely to be the major signpost to the melanomagenic defect.

Entities:  

Mesh:

Year:  1992        PMID: 1561806     DOI: 10.1007/bf02071528

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  58 in total

1.  Gene expression in melanoma cell lines and cultured melanocytes: correlation between levels of c-src-1, c-myc and p53.

Authors:  G Chenevix-Trench; N G Martin; K A Ellem
Journal:  Oncogene       Date:  1990-08       Impact factor: 9.867

2.  Exclusion of the dysplastic nevus syndrome (DNS) locus from the short arm of chromosome 1 by linkage studies in Dutch families.

Authors:  A van Haeringen; W Bergman; M R Nelen; E van der Kooij-Meijs; I Hendrikse; J T Wijnen; P M Khan; E C Klasen; R R Frants
Journal:  Genomics       Date:  1989-07       Impact factor: 5.736

3.  Uveal malignant melanoma and optic nerve glioma in von Recklinghausen's neurofibromatosis.

Authors:  C M Antle; K F Damji; V A White; J Rootman
Journal:  Br J Ophthalmol       Date:  1990-08       Impact factor: 4.638

4.  Clinical aspects of familial cutaneous malignant melanoma.

Authors:  M A Tucker; S J Bale
Journal:  Semin Oncol       Date:  1988-12       Impact factor: 4.929

5.  Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome.

Authors:  M H Greene; W H Clark; M A Tucker; D E Elder; K H Kraemer; D Guerry; W K Witmer; J Thompson; I Matozzo; M C Fraser
Journal:  N Engl J Med       Date:  1985-01-10       Impact factor: 91.245

6.  [von Recklinghausen disease and cutaneous melanoma. A rare association].

Authors:  M T Baldini; F Belli; E Leo; C Bartoli; M Rovati; L Rovati; P Veronesi
Journal:  G Ital Oncol       Date:  1988 Apr-Jun

7.  Localization of the gene for familial adenomatous polyposis on chromosome 5.

Authors:  W F Bodmer; C J Bailey; J Bodmer; H J Bussey; A Ellis; P Gorman; F C Lucibello; V A Murday; S H Rider; P Scambler
Journal:  Nature       Date:  1987 Aug 13-19       Impact factor: 49.962

8.  Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus.

Authors:  D Viskochil; A M Buchberg; G Xu; R M Cawthon; J Stevens; R K Wolff; M Culver; J C Carey; N G Copeland; N A Jenkins
Journal:  Cell       Date:  1990-07-13       Impact factor: 41.582

Review 9.  Cutaneous malignant melanoma in a black patient with neurofibromatosis (von Recklinghausen's disease).

Authors:  J F Silverman; M Blahove; J L Collins; H T Norris
Journal:  Am J Dermatopathol       Date:  1988-12       Impact factor: 1.533

10.  Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Authors:  R Iggo; K Gatter; J Bartek; D Lane; A L Harris
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.